CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features

Seog Yun Park, Myeong Cherl Kook, Young Woo Kim, Nam Yun Cho, Namhee Jung, Hyeongju Kwon, Tae You Kim, Gyeong Hoon Kang

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Gastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found. CpG island methylator phenotype (CIMP) refers to a subset of GCs which harbor concordant methylation of multiple promoter CpG island loci. However, little is known regarding clinicopathological features of CIMP-positive (CIMP-high) GC. Our study aimed to characterize clinicopathological features of CIMP-high GC. We analyzed 196 cases of GCs for their methylation status in 16 cancer-specific CpG island loci using MethyLight assay and arbitrarily defined CIMP-high GC as those with methylation at 13 or more CpG island loci. With exclusion of microsatellite instability-positive GC and EBV-positive GC from the analysis, CIMP-high GC (n∈=∈10, 6.7%) demonstrated tendency toward higher cancer stage, infiltrative growth type, poor differentiation, and diffuse or mixed type of Lauren classification. CIMP-high GC showed significantly shortened survival compared with that of CIMP-negative GC. When CIMP-negative GC (methylation at 12 or less) was divided into CIMP-intermediate and CIMP-low (methylation at one or none), CIMP-low exhibited better clinical outcome than CIMP-intermediate. Hypermethylation at 14 CpG island loci or more was closely associated with poor clinical outcome and found to be an independent prognostic factor. Our findings that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis are distinct from previous studies. More extensive, large-scaled study is necessary to validate the findings of the present study.

Original languageEnglish
Pages (from-to)415-422
Number of pages8
JournalVirchows Archiv
Volume457
Issue number4
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

CpG Islands
Stomach
Carcinoma
Phenotype
Methylation
Neoplasms
Microsatellite Instability

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Park, Seog Yun ; Kook, Myeong Cherl ; Kim, Young Woo ; Cho, Nam Yun ; Jung, Namhee ; Kwon, Hyeongju ; Kim, Tae You ; Kang, Gyeong Hoon. / CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. In: Virchows Archiv. 2010 ; Vol. 457, No. 4. pp. 415-422.
@article{2019e96693a24ee797ecb2aa9d84962d,
title = "CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features",
abstract = "Gastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found. CpG island methylator phenotype (CIMP) refers to a subset of GCs which harbor concordant methylation of multiple promoter CpG island loci. However, little is known regarding clinicopathological features of CIMP-positive (CIMP-high) GC. Our study aimed to characterize clinicopathological features of CIMP-high GC. We analyzed 196 cases of GCs for their methylation status in 16 cancer-specific CpG island loci using MethyLight assay and arbitrarily defined CIMP-high GC as those with methylation at 13 or more CpG island loci. With exclusion of microsatellite instability-positive GC and EBV-positive GC from the analysis, CIMP-high GC (n∈=∈10, 6.7{\%}) demonstrated tendency toward higher cancer stage, infiltrative growth type, poor differentiation, and diffuse or mixed type of Lauren classification. CIMP-high GC showed significantly shortened survival compared with that of CIMP-negative GC. When CIMP-negative GC (methylation at 12 or less) was divided into CIMP-intermediate and CIMP-low (methylation at one or none), CIMP-low exhibited better clinical outcome than CIMP-intermediate. Hypermethylation at 14 CpG island loci or more was closely associated with poor clinical outcome and found to be an independent prognostic factor. Our findings that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis are distinct from previous studies. More extensive, large-scaled study is necessary to validate the findings of the present study.",
author = "Park, {Seog Yun} and Kook, {Myeong Cherl} and Kim, {Young Woo} and Cho, {Nam Yun} and Namhee Jung and Hyeongju Kwon and Kim, {Tae You} and Kang, {Gyeong Hoon}",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s00428-010-0962-0",
language = "English",
volume = "457",
pages = "415--422",
journal = "Virchows Archiv",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "4",

}

Park, SY, Kook, MC, Kim, YW, Cho, NY, Jung, N, Kwon, H, Kim, TY & Kang, GH 2010, 'CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features', Virchows Archiv, vol. 457, no. 4, pp. 415-422. https://doi.org/10.1007/s00428-010-0962-0

CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. / Park, Seog Yun; Kook, Myeong Cherl; Kim, Young Woo; Cho, Nam Yun; Jung, Namhee; Kwon, Hyeongju; Kim, Tae You; Kang, Gyeong Hoon.

In: Virchows Archiv, Vol. 457, No. 4, 01.10.2010, p. 415-422.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features

AU - Park, Seog Yun

AU - Kook, Myeong Cherl

AU - Kim, Young Woo

AU - Cho, Nam Yun

AU - Jung, Namhee

AU - Kwon, Hyeongju

AU - Kim, Tae You

AU - Kang, Gyeong Hoon

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Gastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found. CpG island methylator phenotype (CIMP) refers to a subset of GCs which harbor concordant methylation of multiple promoter CpG island loci. However, little is known regarding clinicopathological features of CIMP-positive (CIMP-high) GC. Our study aimed to characterize clinicopathological features of CIMP-high GC. We analyzed 196 cases of GCs for their methylation status in 16 cancer-specific CpG island loci using MethyLight assay and arbitrarily defined CIMP-high GC as those with methylation at 13 or more CpG island loci. With exclusion of microsatellite instability-positive GC and EBV-positive GC from the analysis, CIMP-high GC (n∈=∈10, 6.7%) demonstrated tendency toward higher cancer stage, infiltrative growth type, poor differentiation, and diffuse or mixed type of Lauren classification. CIMP-high GC showed significantly shortened survival compared with that of CIMP-negative GC. When CIMP-negative GC (methylation at 12 or less) was divided into CIMP-intermediate and CIMP-low (methylation at one or none), CIMP-low exhibited better clinical outcome than CIMP-intermediate. Hypermethylation at 14 CpG island loci or more was closely associated with poor clinical outcome and found to be an independent prognostic factor. Our findings that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis are distinct from previous studies. More extensive, large-scaled study is necessary to validate the findings of the present study.

AB - Gastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found. CpG island methylator phenotype (CIMP) refers to a subset of GCs which harbor concordant methylation of multiple promoter CpG island loci. However, little is known regarding clinicopathological features of CIMP-positive (CIMP-high) GC. Our study aimed to characterize clinicopathological features of CIMP-high GC. We analyzed 196 cases of GCs for their methylation status in 16 cancer-specific CpG island loci using MethyLight assay and arbitrarily defined CIMP-high GC as those with methylation at 13 or more CpG island loci. With exclusion of microsatellite instability-positive GC and EBV-positive GC from the analysis, CIMP-high GC (n∈=∈10, 6.7%) demonstrated tendency toward higher cancer stage, infiltrative growth type, poor differentiation, and diffuse or mixed type of Lauren classification. CIMP-high GC showed significantly shortened survival compared with that of CIMP-negative GC. When CIMP-negative GC (methylation at 12 or less) was divided into CIMP-intermediate and CIMP-low (methylation at one or none), CIMP-low exhibited better clinical outcome than CIMP-intermediate. Hypermethylation at 14 CpG island loci or more was closely associated with poor clinical outcome and found to be an independent prognostic factor. Our findings that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis are distinct from previous studies. More extensive, large-scaled study is necessary to validate the findings of the present study.

UR - http://www.scopus.com/inward/record.url?scp=77958008996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958008996&partnerID=8YFLogxK

U2 - 10.1007/s00428-010-0962-0

DO - 10.1007/s00428-010-0962-0

M3 - Article

C2 - 20737169

AN - SCOPUS:77958008996

VL - 457

SP - 415

EP - 422

JO - Virchows Archiv

JF - Virchows Archiv

SN - 0945-6317

IS - 4

ER -